Global Pulmonary Drug Delivery Devices Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2030

Global Pulmonary Drug Delivery Devices Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2030

Global Pulmonary Drug Delivery Devices Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 – 2030

Global Pulmonary drug delivery devices market was valued at US $35.6 Billion in 2022 and is expected to reach US $48.5 Billion by 2030, growing at a CAGR of 5% during the forecast period 2023-2030.

The purpose of pulmonary drug delivery systems is to inhale medication straight into the lungs. Pharmaceuticals such as bronchodilators, corticosteroids, antibiotics, and other drugs used to treat respiratory disorders such cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections are administered using these devices.

The market is expanding due to factors like the rising prevalence of respiratory illnesses, ongoing technical improvements, and the rising desire for pulmonary drug delivery as an alternate method of medication administration. Asthma, chronic obstructive lung disorders, and other respiratory problems are becoming more and more common in the population, and their prevalence is rising quickly. This pattern is anticipated to increase demand for pulmonary medication delivery systems, driving the market's expansion. For instance, estimates state that by 2050, 645.6 million people—454.4 million men and 191.2 million women—will have COPD, representing a 36% relative rise in the disease's prevalence worldwide over the previous year, according to an August 2022 article in the ERS Journal. As a result, it is anticipated that the prevalence of COPD, a serious public health issue, will rise, particularly in emerging economies. Over the course of the projection period, this spike is expected to fuel demand for different drug delivery systems, including nebulisers and inhalers, thereby catalysing market expansion.

“Metered dose inhalers segment, by product, to be dominating market from 2023 to 2030.”

The segmentation analysis of the pulmonary drug delivery devices market, focusing specifically on dry powder inhalers (DPIs), metered dose inhalers (MDIs), and nebulizers. These devices are vital instruments in the treatment of respiratory disorders like asthma and chronic obstructive pulmonary disease (COPD) because they meet a wide range of patient needs and therapeutic requirements. With a market share of over 60% in 2022, the metered dose inhalers sector solidified its leadership in the worldwide market for pulmonary medication delivery devices. The creative metered dose inhalers created by major industry participants have drawn a lot of customer interest, securing this segment's leadership position globally. The metered dose inhalers market has grown as a result of increased consumer acceptance of these devices and the rising incidence of pulmonary disorders. On the other hand, it is anticipated that during the forecast period, the nebulisers segment will develop at the fastest rate. Nebulisers are a great option for both at-home and emergency use because of their many benefits, which include simple administration of big doses, user comfort, and favourable reimbursement policies. As such, it is anticipated that this market will continue to grow quickly in the near future.

“COPD segment, by disease, to be fastest growing market from 2023 to 2030.”

The segmentation analysis of the pulmonary drug delivery devices market, focusing specifically on Allergic Rhinitis, Asthma, COPD and Cystic Fibrosis. The high mortality and prevalence of COPD are linked to the condition's rapid expansion in the market. The consistent revenue growth in this market is also attributed to beneficial reimbursement rules for COPD treatment and the expansion of governmental and non-governmental organisations providing COPD care. Owing to these factors, it is expected that the COPD market would continue to develop.

“North America to be largest region in Pharmacy Automation Market.”

By region, the market is divided into North America, Europe, APAC, and Others. Others is further divided into Middle East and South America. It is anticipated that North America will have significant growth in the field of pulmonary medication delivery systems during the course of the forecast period. Numerous factors contribute to this expansion, such as the rising incidence of respiratory conditions like COPD, asthma, and allergic rhinitis, as well as an ageing population, a larger need for diagnostic tools, higher healthcare costs, and more disposable income.

The rising incidence of respiratory illnesses in the general population is a major driver of this market's expansion, as it highlights the need for drug delivery systems that can address a range of ailments.For instance, a noteworthy correlation was found in an MDPI article from November 2021. It was shown that there is a strong association between respiratory problems and asthmatic children in Mexico City. This association can be linked to traffic-related air pollution. Asthma sufferers' conditions are made worse by this.

The rising incidence of respiratory illnesses among people is a major driver of this market's expansion, highlighting the need for drug delivery systems thatThe country's concentration on producing efficient pulmonary medications, along with the presence of significant market players and the increasing use of different business strategies such as partnerships, agreements, acquisitions, and a growing number of product launches, are expected to drive market expansion.

For example, the US FDA approved the first generic version of Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol in March 2022, marking a major milestone. This approval included the management of airflow obstruction and the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and/or emphysema, as well as the treatment of asthma in patients six years of age and older.

As a result, it is projected that the growing prevalence of respiratory illnesses as well as the increased volume of business ventures and product launches in the nation will be significant factors propelling the North American market throughout the research period.Due to various circumstances. For instance, a noteworthy correlation was found in an MDPI article from November 2021. It was shown that there is a strong association between respiratory problems and asthmatic children in Mexico City. This association can be linked to traffic-related air pollution. Asthma sufferers' conditions are made worse by this.

Pharmacy Automation Competitive Landscape

The competitive landscape of the Pharmacy Automation Market involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats of the industry. Key industry players have recognized that the adoption of Pharmacy Automation technology holds the potential for further growth. The growing desire among producers to optimize their production costs has spurred collaborative efforts among companies to scale up their production capacity. This strategic collaboration not only aims to increase revenue but also seeks to establish dominance in the market.

The Pharmacy Automation Market is highly competitive, with numerous companies vying for market share. Prominent companies in the Pharmacy Automation Market include:

Major Players:

GlaxoSmithKline (GSK)

AstraZeneca

Boehringer Ingelheim

Teva Pharmaceuticals

Novartis

Others

Recent Developments:

In April 2023, PurelMS, a clinical-stage pharmaceutical business, announced the opening of a fresh investment round by the independent private foundation Boost-UP Foundation. Apart from its continuous financial contributions, the foundation proactively endeavours to stimulate pharmaceutical and biotechnology firms to engage in preclinical research projects with the objective of creating a diverse array of molecules, varying in size, for both localised and systemic uses.

In mid-2023, Recipharm, a prominent Contract Development and Manufacturing Organisation (CDMO), partnered with Stevanato Group S.p.A., a widely acknowledged supplier of drug delivery, containment, and diagnostics solutions to the pharmaceutical and biotechnology industries. The goal of this collaboration is to enable Recipharm's soft mist inhalers to accept pre-fillable syringes. To assist with the creation and manufacturing of these syringes, Stevanato Group will make use of its manufacturing experience. Stevanato Group will provide and produce its glass pre-fillable syringe, known as Alba, as part of this agreement. Using the Integration Spray Module (ISMTM), this syringe will be easily connected with Recipharm's gentle mist inhalation technology, which is known as the Pre-Filled Syringe Inhaler (PFSITM).

In September 2022, RIGImmune completed the acquisition of Subintro, giving the biotech business access to cutting-edge topical delivery technologies. With this calculated approach, RIGImmune can move faster towards creating novel RNA treatments and adjuvants for vaccines meant to be administered locally to mucosal surfaces.

Aptar Pharma obtained a worldwide licence for the Orbital Dry Powder Inhaler (DPI) in August 2022. With this purchase, Aptar Pharma will be better positioned to respond to the growing global need for the safe and convenient administration of high-dose therapies to the respiratory system.